unbekannter Gast

Kurt Zatloukal#


Professor of Pathology, Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz; phone: +43-316-380 4404, fax: +43-316-384 329, e-mail: kurt.zatloukal@medunigraz.at

Personal Data

Date of Birth: March 4th, 1959
Place of Birth: Graz, Austria
Nationality: Austrian


1977-1985: Medical School, University of Graz
1985: M.D. degree (Dr.)
Career History

1985-1991: Residence for pathologist at the Institute of Pathology, University of Graz, Austria (Head: Prof. Helmut Denk), with specialization in Molecular Pathology
1992: Habilitation in Molecular Pathology
1991-1993: Postdoc at the Research Institute of Molecular Pathology (I.M.P), Vienna,Austria, in the group of Prof. Max L. Birnstiel (development of gene therapies for cancer)
1997: Professor of Pathology
Career-related Activities & Memberships

2000 – 2003: Member of the board of the Austrian Science Fund
2001 - 2009: Member of the Bioethics Commission at the Federal Chancellery
2001: Founder of Oridis-Biomed (CEO 2001-2005)
2002 - 2005: President of the Austrian Society of Genetics and Gene Technology
2002: Corresponding member of the Austrian Academy of Sciences
2002 - 2007: Member of the OECD task force on biological resource centres
2004 - 2011 Member of the Roadmap (thematic) Working Group of the European Strategy Forum on Research Infrastructure (ESFRI)
2009: Member of the Austrian “Arzneimittelbeirat”
2009: Santa Chiara Chair at the University of Siena
2009: Honorary Professor of the University of Dundee
2010: Director of the Christian Doppler Laboratory “ Biospecimen Research and Biobanking Technologies”


155 publications, 14 patents

Research Fields:

The research work focuses on molecular pathology of metabolic liver diseases and cancer. Kurt Zatloukal coordinated the preparatory phase of a European biobanking and biomolecular research infrastructure (BBMRI) within the 7th EU framework programme. BBMRI should provide access to high quality human biological samples to enable future needs of large genetic epidemiology and sequencing studies. In this context it is crucial to establish Europe-wide harmonized processes and quality criteria that are compliant with the requirements of latest -omics technologies as well as with ethical and legal regulations. Furthermore, he leads in the FP7-funded large integrated project SPIDIA the development of new European standards and norms for tissue-based biomarkers, and leads the medical platform of the FET Flagship project IT Future of Medicine.

Kurt Zatloukal was member of the OECD task force on biological resource centres and the Roadmap Working Group of the European Strategy Forum on Research Infrastructures. Moreover, he contributed to the OECD best practice guidelines for biological resource centres, the regulations for genetic testing of the Austrian Gene Technology Law, and the opinion on Biobanks for research of the Bioethics Commission at the Austrian Federal Chancellery.